BIO Bio-Rad Laboratories Inc
- Stocks
- Healthcare
- NYSE: BIO
Price (delayed)
$264.21
Market cap
$7.15B
P/E Ratio
22.28
Dividend/share
N/A
EPS
$11.86
Enterprise value
$8.19B
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley,
Highlights
The EPS has soared by 125% YoY and by 116% from the previous quarter
The net income has soared by 124% YoY and by 115% QoQ
The company's quick ratio fell by 21% YoY and by 18% QoQ
The debt is up by 2.7% since the previous quarter
Key stats
What are the main financial stats of BIO
Market
Valuations
Earnings
Shares outstanding
27.06M
Market cap
$7.15B
Enterprise value
$8.19B
Price to earnings (P/E)
22.28
Price to book (P/B)
1.01
Price to sales (P/S)
2.82
EV/EBIT
16.41
EV/EBITDA
16.41
EV/Sales
3.21
Revenue
$2.55B
Gross profit
$1.35B
Operating income
$223.6M
Net income
$319.17M
EBIT
$499.06M
EBITDA
$499.06M
Free cash flow
$371.03M
Per share
Balance sheet
Liquidity
EPS
$11.86
EPS diluted
$11.83
Free cash flow per share
$13.63
Book value per share
$261.96
Revenue per share
$93.81
TBVPS
$339.22
Total assets
$10.21B
Total liabilities
$3.09B
Debt
$1.41B
Equity
$7.13B
Working capital
$2.26B
Debt to equity
0.2
Current ratio
5.12
Quick ratio
3.36
Net debt/EBITDA
2.08
Margins
Efficiency
Dividend
EBITDA margin
19.5%
Gross margin
52.8%
Net margin
12.5%
Operating margin
8.8%
Return on assets
3.2%
Return on equity
4.6%
Return on invested capital
5.2%
Return on capital employed
5.2%
Return on sales
19.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIO stock price
How has the Bio-Rad Laboratories stock price performed over time
Intraday
-0.4%
1 week
-7.16%
1 month
5.38%
1 year
-19.54%
YTD
-19.57%
QTD
9.49%
Financial performance
How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.55B
Gross profit
$1.35B
Operating income
$223.6M
Net income
$319.17M
Gross margin
52.8%
Net margin
12.5%
The net margin has surged by 124% year-on-year and by 115% since the previous quarter
The net income has soared by 124% YoY and by 115% QoQ
BIO's operating income is down by 33% year-on-year and by 10% since the previous quarter
BIO's operating margin is down by 32% year-on-year and by 10% since the previous quarter
Price vs fundamentals
How does BIO's price correlate with its fundamentals
Growth
What is Bio-Rad Laboratories's growth rate over time
Valuation
What is Bio-Rad Laboratories stock price valuation
P/E
22.28
P/B
1.01
P/S
2.82
EV/EBIT
16.41
EV/EBITDA
16.41
EV/Sales
3.21
The EPS has soared by 125% YoY and by 116% from the previous quarter
BIO's P/B is 28% below its 5-year quarterly average of 1.4 and 8% below its last 4 quarters average of 1.1
The equity has grown by 7% from the previous quarter and by 5% YoY
The stock's price to sales (P/S) is 42% less than its 5-year quarterly average of 4.9 and 9% less than its last 4 quarters average of 3.1
Efficiency
How efficient is Bio-Rad Laboratories business performance
The company's return on invested capital has surged by 135% YoY and by 118% QoQ
The ROS has soared by 130% YoY and by 118% from the previous quarter
The ROE has soared by 129% year-on-year and by 115% since the previous quarter
Bio-Rad Laboratories's ROA has soared by 128% YoY and by 114% from the previous quarter
Dividends
What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIO.
Financial health
How did Bio-Rad Laboratories financials performed over time
The company's quick ratio fell by 21% YoY and by 18% QoQ
The company's current ratio fell by 18% YoY and by 15% QoQ
The debt is 80% smaller than the equity
The equity has grown by 7% from the previous quarter and by 5% YoY
Bio-Rad Laboratories's debt to equity has decreased by 4.8% from the previous quarter and by 4.8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.